Tissue Regeneration Therapeutics Inc.

Presenter: John E. Davies, President & CEO

Company Information

Company Type: Therapeutics

Development Stage: Private

Company Profile

Tissue Regeneration Therapeutics (TRT) is a life science company that has discovered the world's richest source of mesenchymal stromal cells (MSCs). These cells give rise to all those that differentiate into the tissues of the musculo-skeletal system, e.g. bone, cartilage, and muscle, and they also possess unique immuno-regulatory properties and can thus be used to treat immune and inflammatory diseases. TRT extracts this population of cells from the tissue around the blood vessels of the umbilical cord, and calls them Human Umbilical Cord PeriVascular Cells (HUCPVCs). MSCs, most commonly harvested in small numbers from the bone marrow of adult volunteers, are in clinical development internationally by many companies and research groups to treat a wide variety of diseases and tissue regenerative therapies. The unique TRT advantages are founded on the highly enriched source of these very important cells, their increased biological potential compared to those from adult donors, and their inexhaustible supply. TRT has filed for broad international coverage for an extended family of HUCPVC-related patents the first of which have already been allowed in Australia and the USA.

BUSINESS MODEL
Unlike most early-stage biotechnology companies, TRT has developed a product which has reached the market. CReATe Cord Blood Bank, the Company's Canadian licensee, stores HUCPVCs, marketed as Peristem(TM), harvested at birth for long-term family stem cell banking. HUCPVC banking is offered as an additional service to cord blood banking, itself a rapidly growing industry. At CReATe, over 50% of parents storing their babies cord blood also choose to store Peristem(TM) TRT receives a royalty on every cord collected. This technology is also licensed for the Middle East, with additional international licenses in various stages of development.

As a second product application of HUCPVCs, the Company is developing the use of these cells as internal sources of therapeutic antibodies to potential agents of bioterrorism (stealth cells). When completely developed, transfected cells will continue to produce antibodies to infectious organisms in front-line responders and emergency personnel long after exposure. This product is being developed in conjunction with the research arm of the Canadian military, and is expected to utilize the FDA's animal efficacy rule to greatly shorten its time to market.

Finally, the Company is developing HUCPVCs for cellular therapy and regenerative medicine. Although only at the very early stages of development, this product application has already attracted the interest of multinational life science companies.
In addition to the HUCPVC product lines, TRT's wholly owned subsidiary, BoneTec, has developed a bone substitute and scaffold to be used in healing bone defects. OsteoScaf is fully resorbable, osteoconductive, and mechanically strong, and generates no inflammatory response. TRT has formed a joint venture with a U.S. company to commercialize OsteoScaf. It is in the process of filing for FDA approval through a 510(K) filing, and is expected to be on the market during the current year. Future work will integrate HUCPVCs onto OsteoScaf to make a second-generation living bone graft.

Contact

Tissue Regeneration Therapeutics Inc.
790 Bay Street, Suite 512, P.O. Box 55
Toronto
Ontario, Canada
M5R 1R4

ph: 416-345-0039
fx: 416-345-9277

www.verypowerfulbiology.com
info@verypowerfulbiology.com